Last reviewed · How we verify
NCT02681328
Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules
trial testing Afirma GEC in Thyroid in 328 participants. Participants enrolled and being followed up; not accepting new ones.
1 December 2026
Quick facts
| Lead sponsor | Jonsson Comprehensive Cancer Center |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 328 |
| Start date | 1 May 2016 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Afirma GEC
- ThyroSeq v.2
- Afirma GSC
- ThyroSeq v.3
Conditions studied
- Thyroid — all drugs for Thyroid →
Sponsor
Jonsson Comprehensive Cancer Center — full company profile →
Who can join
Adults 18 to 100, any sex, with Thyroid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to compare the performance of Afirma GSC and ThyroSeq v.3 in indeterminate thyroid nodules to determine which test can allow more patients to avoid unnecessary surgery and preserve quality of life. In the initial phase of this study, the performance of Afirma GEC and ThyroSeq v.2 were compared.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial.
Livhits MJ, Zhu CY, Kuo EJ, Nguyen DT, et al · · 2021 · cited 132× · PMID 33300952 · DOI 10.1001/jamaoncol.2020.5935 -
The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
Hu TX, Nguyen DT, Patel M, Beckett K, et al · · 2022 · cited 17× · PMID 35611970 · DOI 10.1089/thy.2021.0659
Verify or expand the search:
- PubMed search for NCT02681328
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid
Currently open trials in the same condition.
- NCT07296575 — Ultrasound Large-scale Model in Thyroid Field: A Multi-center Study on Medical-Engineering Integration · active not recruiting
- NCT06800482 — A Study of Online Follow-up in Patients With Papillary Thyroid Cancer · NA · recruiting
- NCT04845867 — A Prospective, Single-arm, Multi-centre, Blinded, Observational, Diagnostic Accuracy Study With a Diagnostic Medical Pro · recruiting
- NCT06419556 — Analgesic Efficacy of an Intermediate CPB in Neck Surgeries. · NA · recruiting
- NCT05733013 — A Study to Collect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid Cancer · recruiting
Other Jonsson Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
- NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
- NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
- NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02681328 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
- Last refreshed: 22 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02681328.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing